161 related articles for article (PubMed ID: 11348363)
1. Assessment of Tissue Estrogen and Progesterone Receptor Levels: A Survey of Current Practice, Techniques, and Quantitation Methods.
Layfield LJ; Gupta D; Mooney EE
Breast J; 2000 May; 6(3):189-196. PubMed ID: 11348363
[TBL] [Abstract][Full Text] [Related]
2. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories.
Regitnig P; Reiner A; Dinges HP; Höfler G; Müller-Holzner E; Lax SF; Obrist P; Rudas M; Quehenberger F
Virchows Arch; 2002 Oct; 441(4):328-34. PubMed ID: 12404057
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Estrogen and Progesterone Receptor Antibody Reagents Using Proficiency Testing Data.
Troxell ML; Long T; Hornick JL; Ambaye AB; Jensen KC
Arch Pathol Lab Med; 2017 Oct; 141(10):1402-1412. PubMed ID: 28714765
[TBL] [Abstract][Full Text] [Related]
4. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.
Allred DC; Carlson RW; Berry DA; Burstein HJ; Edge SB; Goldstein LJ; Gown A; Hammond ME; Iglehart JD; Moench S; Pierce LJ; Ravdin P; Schnitt SJ; Wolff AC
J Natl Compr Canc Netw; 2009 Sep; 7 Suppl 6():S1-S21; quiz S22-3. PubMed ID: 19755043
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.
Rhodes A; Jasani B; Balaton AJ; Miller KD
J Clin Pathol; 2000 Apr; 53(4):292-301. PubMed ID: 10823126
[TBL] [Abstract][Full Text] [Related]
6. Estrogen and progesterone receptor assay in paraffin-embedded breast cancer--reproducibility of assessment.
Chebil G; Bendahl PO; Fernö M; ;
Acta Oncol; 2003; 42(1):43-7. PubMed ID: 12665330
[TBL] [Abstract][Full Text] [Related]
7. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program.
Francis GD; Dimech M; Giles L; Hopkins A
J Clin Pathol; 2007 Nov; 60(11):1277-83. PubMed ID: 17259294
[TBL] [Abstract][Full Text] [Related]
8. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
[TBL] [Abstract][Full Text] [Related]
9. Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: prognostic significance.
Layfield LJ; Saria EA; Conlon DH; Kerns BJ
J Surg Oncol; 1996 Mar; 61(3):177-84. PubMed ID: 8637203
[TBL] [Abstract][Full Text] [Related]
10. Significance of immunohistochemical assessment of steroid hormone receptor status for breast cancer patients.
Kurosumi M
Breast Cancer; 2003; 10(2):97-104. PubMed ID: 12736561
[TBL] [Abstract][Full Text] [Related]
11. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
12. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials.
Alberts SR; Ingle JN; Roche PR; Cha SS; Wold LE; Farr GH; Krook JE; Wieand HS
Cancer; 1996 Aug; 78(4):764-72. PubMed ID: 8756370
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of estrogen and progesterone receptors performed with an antigen-retrieval technique on methacarn-fixed paraffin-embedded breast cancer tissues.
Oyaizu T; Arita S; Hatano T; Tsubura A
J Surg Res; 1996 Jan; 60(1):69-73. PubMed ID: 8592434
[TBL] [Abstract][Full Text] [Related]
14. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer--clinical associations and reasons for discrepancies.
Chebil G; Bendahl PO; Idvall I; Fernö M
Acta Oncol; 2003; 42(7):719-25. PubMed ID: 14690157
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies.
Hicks D; Dell'Orto P; Falzon M; Hoff KD; Levy YY; McMahon L; Miller K; Russo L; Viale G
Appl Immunohistochem Mol Morphol; 2017; 25(5):313-319. PubMed ID: 26657878
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
[TBL] [Abstract][Full Text] [Related]
18. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.
Encarnación CA; Ciocca DR; McGuire WL; Clark GM; Fuqua SA; Osborne CK
Breast Cancer Res Treat; 1993; 26(3):237-46. PubMed ID: 8251648
[TBL] [Abstract][Full Text] [Related]
19. Impact of standardization of estrogen and progesterone receptor assays of breast cancer biopsies in Denmark.
Thorpe SM; Poulsen HS; Pedersen KO; Rose C
Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1263-9. PubMed ID: 3181248
[TBL] [Abstract][Full Text] [Related]
20. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
